Generation and characterization of recombinant vaccinia viruses expressing a hepatitis C virus Core protein, genotype 1b, individually or as a polyprotein

Biotecnologia Aplicada

Volumn 24, Issue 3-4, 2007, Pages 246-253

  Alvarez Lajonchere, Liz ^a   Guerra, Ivis ^a   Amador Cañizares, Yalena ^a   Frías, Roberto ^a   Vazquez Blomquist, Dania ^a   Morales, Juan ^a   Dueñas Carrera, Santiago ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Cellular immunity; HCV; IFN gamma; Replication; Vaccinia

Indexed keywords

CORE PROTEIN; GAMMA INTERFERON; POLYPROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRUS CHARACTERIZATION; VIRUS LOAD; VIRUS RECOMBINANT; WESTERN BLOTTING;

ANIMALIA; HEPATITIS C VIRUS; MUS; VACCINIA VIRUS;

EID: 49249133111     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Cameron AM, Busuttil RW. The status of liver transplantation for hepatitis C. Expert Opin Biol Ther (2006); 6:993-1002.
2. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. (2006); 10:697-715.
3. Koike K. Antiviral treatment of hepatitis C: present status and future prospects. J Infect Chemother (2006); 12:227-32.
4. Azzam HS, Goertz C, Fritts M, Jonas WB. Natural products and chronic hepatitis C virus. Liver Int (2007); 27:17-25.
5. Bartenschlager R, Kaul A, Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res (2003); 60:91-102.
6. Kuzushita N, Gregory SH, Monti NA, Carlson R, Gehring S, Wands JR. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology. (2006); 130:453-64.
7. Alatrakchi N, Graham CS, He Q, Sherman KE, Koziel MJ. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection. J Infect Dis. (2005); 191:702-9.
8. Eisenbach C, Freyse A, Lupu CM, Weigand K, Ernst E, Hoyler B, Stremmel W et al. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse. Vaccine. (2006); 24:5140-8.
9. Oka K, Nagano-Fujii M, Yoshida I, Hidajat R, Deng L, Akutsu M et al. hepatitis C Virus Core Protein Selectively Inhibits Synthesis and Accumulation of p21/Waf1 and Certain Nuclear Proteins. Microbiol Immunol (2003); 47:429-38.
10. Li D, Takyar ST, Lott WB, Gowans EJ. Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells. J Gen Virol (2003); 84:815-25.
11. Houghton M, Weiner A, Han J, Kuo G, Choo Q-L. Molecular biology of the hepatitis C virus: implications for diagnosis, development, and control of viral disease. Hepatology (1991); 14:381-6.
12. Acosta-Rivero N, Rodriguez A, Musacchio A, Falcon V, Suarez VM, Chavez L et al. Nucleic acid binding properties and intermediates of HCV core protein multimerization in Pichia pastoris. Biochem Biophys Res Commun (2004); 323:926-31.
13. Ray RB, Ray R. hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol Lett (2001); 202:149-56.
14. Hassan M, Ghozlan H, Abdel-Kader O. Activation of RB/E2F signaling pathway is required forthe modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells. Cell Signal (2004); 16:1375-85.
15. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002); 196:641-53.
16. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest (2000); 106:1239-49.
17. Álvarez-Obregon JC, Dueñas-Carrera S, Valenzuela C, Morales J. A truncated HCV core protein elicits a potent immune response with a strong participation of cellular immunity components in mice. Vaccine (2001); 19:3940-6.
18. Martínez-Donato G, Acosta-Rivero N, Morales-Grillo J, Musacchio A, Vina A, Álvarez C etal. Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast. Biochem Biophys Res Commun (2006); 342: 625-631.
19. Houghten RA, DeGraw ST, Bray MK, Hoffmann SR, Frizzell ND. Simultaneous Multiple Peptide Synthesis: The Rapid Preparation of Large Numbers of Discrete Peptides for Biological, Immunological, and Methodological Studies. Biotechniques (1986); 4:522-6.
20. Vázquez MI., Esteban M. Identification of Functional Domains in the 14-Kilodalton Envelope Protein (A27L) of Vaccinia Virus. J Virol (1999); 73:9098-109.
21. Dueñas-Carrera S, Álvarez-Lajonchere L, Alvarez- Obregón JC, Herrera A, Lorenzo LJ, Pichardo D et al. A truncated variant of the hepatitis C virus core induces a slow but potent immune response in mice following DNA immunization. Vaccine (2000); 19:992-7.
22. Dueñas-Carrera S, Álvarez-Lajonchere L, Álvarez- Obregón JC, Pérez A, Acosta-Rivero N, Vázquez DM et al. Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem (2002); 35:205-12.
23. Morales J, Viña A, García C, Acosta-Rivero N, Dueñas-Carrera S, García O et al. Sequences derived from the genome of the hepatitis C virus, and use thereof. WO 98/25960, 1998.
24. Bronson LH, Parker RF. The neutralization of vaccine virus by immune serum: titration by the intracerebral inoculation of mice. J Bacteriol (1941); 41:56-7.
25. Mayr A, Malicki K. Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus. Zentralbl Veterinarmed B (1966);13:1-13.
26. Álvarez-Lajonchere L, Dueñas Carrera S, Guerra I, Acosta-Rivero N, Musacchio A, Vázquez M, Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis C virus. WO/2006/015557, 2006.
27. Álvarez-Lajonchere L, Amador-Cañizares Y, Frías R, Milian Y, Musacchio A, Guerra I et al. Immunization with a recombinant fowl pox virus expressing a hepatitis C virus Core-E1 polyprotein variant protects mice and monkeys against challenge with a surrogate vaccinia virus. Biotechnology and Applied Biochemistry. In press, 2008.
28. Brockman WW, Nathans D. The isolation of simian virus 40 variants with specifically altered genomes. Proc Natl Acad Sci USA (1974);71:942-6.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970); 227: 680-5.
30. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamides gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA (1981); 769:4350-4.
31. Falcon V, García C, de la Rosa MC, Menéndez I, Seoane J, Grillo JM. Ultrastructural and immunocytochemical evidences of core-particle formation in the methylotrophic Pichia pastoris yeast when expressing HCV structural proteins (core-E1). Tissue Cell (1999);31:117-125.
32. Martínez-Donato G, Vina A, Borges M, Martínez E, Morales-Grillo J. Humoral immune response against a hepatitis C Virus Envelope E2 variant expressed in Escherichia coli. Biotecnologia Aplicada (2000); 17:231-4.
33. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005); 41:847-56.
34. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recuitured in vitro. Proc Natl Acad Sci USA (2006); 103:3805-9.
35. Vázquez MI, Rivas G, Cregut D, Serrano L, Esteban M. The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal alpha-helix. J Virol (1998); 72:10126-37.
36. Broder CC and Earl P. Recombinat vaccinia viruses: Design, Generation an Isolation. Molecular Biotechnology (1999); 13:223-45.
37. Chan KS, Verardi PH, Legrand FA, Yilma TD. Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus. Proc Natl Acad Sci USA (2005); 102:8734-9.
38. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, and Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA (2003); 100:6753-8.
39. Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine (2003); 21:1629-39.
40. Large MK, Kittlesen DJ, Hahn YS. Suppression of Host Immune Response by the Core Protein of hepatitis C Virus: Possible Implications for hepatitis C Virus Persistence. J Immunol (1999); 162:931-8.
41. Binder D, Küding TM. Antiviral protection by CD8+versus CD4+T cells. CD8+T cells correlating with cytotoxic activity in vitro are more efficient in antivaccinia virus protection than CD4-dependent IL. J Immunol (1991); 146:4301-7.
42. Kronenberger B, Sarrazin C, Hofmann WP, von Wagner M, Herrmann E, Welsch C et al. Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. J Viral Hepat (2004); 11:310-8.
43. Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A et al. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol (2003); 98: 1377-83.
44. Zhang H. Lethality in mice infected with recombinant vaccinia virus expressing hepatitis C virus core protein. Hepatobiliary Pancreat Dis Int (2003); 2:374-82.
45. Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994); 68:3334-42.
46. Shirai M, Chen M, Arichi T, Masaki T, Nishioka M, Newman M et al. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J Infect Dis (1996); 173:24-31.
47. Vemulapalli R, Cravero S, Calvert CL, Toth TE, Sriranganathan N, Boyle SM et al. Characterization of Specific Immune Responses of Mice Inoculated with Recombinant Vaccinia Virus Expressing an 18-Kilodalton Outer Membrane Protein of Brucella abortus. Clin Diagn Lab Immunol (2000); 7:114-8.
48. Harrington LE, van der Most R, Whitton JL, and Ahmed R. Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope. J Virol (2002); 76:3329-37.
49. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature (2005); 436:939-45.
50. Giannini C, Brechot C. hepatitis C virus biology. Cell Death Differ (2003); 10:27-38.
51. Liu ZX, Nishida H, He JW, Lai MM, Feng N, Dennert G. hepatitis C virus genotype 1b core protein does not exert immunomodulatory effects on virus-induced cellular immunity. J Virol (2002); 76:990-6.
52. Hunziker IP, Grabscheid B, Zurbriggen R, Gluck R, Pichler WJ, Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int Immunol (2002); 14:615-26.
53. Acosta-Rivero N, Aguilera Y, Falcon V, Poutou J, Musacchio A, Alvarez-Lajonchere A et al. Ultrastructural and Immunological Characterization of hepatitis C Core Protein-DNA Plasmid Complexes. Am J Immunol (2006); 2:67-72.